Kanada - englanti - Health Canada

ivax pharmaceuticals incorporated - famotidine - tablet - 20mg - famotidine 20mg - histamine h2-antagonists

Kanada - englanti - Health Canada

ivax pharmaceuticals incorporated - famotidine - tablet - 40mg - famotidine 40mg - histamine h2-antagonists

Kanada - englanti - Health Canada

sanis health inc - famotidine - tablet - 20mg - famotidine 20mg - histamine h2-antagonists

Kanada - englanti - Health Canada

sanis health inc - famotidine - tablet - 40mg - famotidine 40mg - histamine h2-antagonists

Yhdysvallat - englanti - NLM (National Library of Medicine)

bryant ranch prepack - famotidine (unii: 5qzo15j2z8) (famotidine - unii:5qzo15j2z8) - famotidine 20 mg - famotidine tablets are indicated in adult and pediatric patients 40 kg and greater for the treatment of: - active duodenal ulcer (du). - active gastric ulcer (gu). - symptomatic nonerosive gastroesophageal reflux disease (gerd). - erosive esophagitis due to gerd, diagnosed by biopsy. famotidine tablets are indicated in adults for the: - treatment of pathological hypersecretory conditions (e.g., zollinger-ellison syndrome, multiple endocrine neoplasias). - reduction of the risk of duodenal ulcer recurrence. famotidine tablets are contraindicated in patients with a history of serious hypersensitivity reactions (e.g., anaphylaxis) to famotidine or other histamine-2 (h2 ) receptor antagonists. risk summary available data with h2 -receptor antagonists, including famotidine, in pregnant women are insufficient to establish a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. in animal reproduction studies, no adverse development effects were observed with oral administrat

Yhdysvallat - englanti - NLM (National Library of Medicine)

bryant ranch prepack - famotidine (unii: 5qzo15j2z8) (famotidine - unii:5qzo15j2z8) - famotidine 20 mg - famotidine tablets are indicated in adult and pediatric patients 40 kg and greater for the treatment of: - active duodenal ulcer (du). - active gastric ulcer (gu). - symptomatic nonerosive gastroesophageal reflux disease (gerd). - erosive esophagitis due to gerd, diagnosed by biopsy. famotidine tablets are indicated in adults for the: - treatment of pathological hypersecretory conditions (e.g., zollinger-ellison syndrome, multiple endocrine neoplasias). - reduction of the risk of duodenal ulcer recurrence. famotidine tablets are contraindicated in patients with a history of serious hypersensitivity reactions (e.g., anaphylaxis) to famotidine or other histamine-2 (h2 ) receptor antagonists. risk summary available data with h2 -receptor antagonists, including famotidine, in pregnant women are insufficient to establish a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. in animal reproduction studies, no adverse development effects were observed with oral administrat

Yhdysvallat - englanti - NLM (National Library of Medicine)

mckesson corporation - famotidine (unii: 5qzo15j2z8) (famotidine - unii:5qzo15j2z8) - famotidine 20 mg - famotidine is indicated in: 1. short-term treatment of active duodenal ulcer . most adult patients heal within 4 weeks; there is rarely reason to use famotidine at full dosage for longer than 6 to 8 weeks. studies have not assessed the safety of famotidine in uncomplicated active duodenal ulcer for periods of more than eight weeks. 2. maintenance therapy for duodenal ulcer patients at reduced dosage after healing of an active ulcer. controlled studies in adults have not extended beyond one year. 3. short-term treatment of active benign gastric ulcer. most adult patients heal within 6 weeks. studies have not assessed the safety or efficacy of famotidine in uncomplicated active benign gastric ulcer for periods of more than 8 weeks. 4. short-term treatment of gastroesophageal reflux disease (gerd). famotidine is indicated for short- term treatment of patients with symptoms of gerd (see clinical pharmacology in adults, clinical studies). famotidine is also indicated for the short-term treatment of esophagitis

Yhdysvallat - englanti - NLM (National Library of Medicine)

carilion materials management - famotidine (unii: 5qzo15j2z8) (famotidine - unii:5qzo15j2z8) - famotidine 40 mg - famotidine tablets are indicated in: 1. . most adult patients heal within 4 weeks; there is rarely reason to use famotidine at full dosage for longer than 6 to 8 weeks. studies have not assessed the safety of famotidine in uncomplicated active duodenal ulcer for periods of more than eight weeks. short term treatment of active duodenal ulcer 2. maintenance therapy for duodenal ulcer patients at reduced dosage after healing of an active ulcer. controlled studies in adults have not extended beyond one year. 3. . most adult patients heal within 6 weeks. studies have not assessed the safety or efficacy of famotidine in uncomplicated active benign gastric ulcer for periods of more than 8 weeks. short term treatment of active benign gastric ulcer 4. famotidine is indicated for short term treatment of patients with symptoms of gerd (see ). short term treatment of gastroesophageal reflux disease (gerd). clin

Yhdysvallat - englanti - NLM (National Library of Medicine)

fresenius kabi usa, llc - famotidine (unii: 5qzo15j2z8) (famotidine - unii:5qzo15j2z8) - famotidine 10 mg in 1 ml - famotidine injection, supplied as a concentrated solution for intravenous injection, is intended for intravenous use only. famotidine injection is indicated in some hospitalized patients with pathological hypersecretory conditions or intractable ulcers, or as an alternative to the oral dosage forms for short term use in patients who are unable to take oral medication for the following conditions: - short term treatment of active duodenal ulcer . most adult patients heal within 4 weeks; there is rarely reason to use famotidine at full dosage for longer than 6 to 8 weeks. studies have not assessed the safety of famotidine in uncomplicated active duodenal ulcer for periods of more than 8 weeks. - maintenance therapy for duodenal ulcer patients at reduced dosage after healing of an active ulcer. controlled studies in adults have not extended beyond one year. - short term treatment of active benign gastric ulcer. most adult patients heal within 6 weeks. studies have not assessed the safety or eff

Yhdysvallat - englanti - NLM (National Library of Medicine)

hikma pharmaceuticals usa inc. - famotidine (unii: 5qzo15j2z8) (famotidine - unii:5qzo15j2z8) - famotidine 10 mg in 1 ml - famotidine injection, supplied as a concentrated solution for intravenous injection, is intended for intravenous use only. famotidine injection is indicated in some hospitalized patients with pathological hypersecretory conditions or intractable ulcers, or as an alternative to the oral dosage forms for short term use in patients who are unable to take oral medication for the following conditions: - short term treatment of active duodenal ulcer . most adult patients heal within 4 weeks; there is rarely reason to use famotidine at full dosage for longer than 6 to 8 weeks. studies have not assessed the safety of famotidine in uncomplicated active duodenal ulcer for periods of more than eight weeks. - maintenance therapy for duodenal ulcer patients at reduced dosage after healing of an active ulcer . controlled studies in adults have not extended beyond one year. - short term treatment of active benign gastric ulcer . most adult patients heal within 6 weeks. studies have not assessed the safety or efficacy of famotidine in uncomplicated active benign gastric ulcer for periods of more than 8 weeks. - short term treatment of gastroesophageal reflux disease (gerd) . famotidine is indicated for short term treatment of patients with symptoms of gerd (see clinical pharmacology in adults, clinical studies ). famotidine is also indicated for the short term treatment of esophagitis due to gerd including erosive or ulcerative disease diagnosed by endoscopy (see clinical pharmacology in adults, clinical studies ). - treatment of pathological hypersecretory conditions (e.g., zollinger-ellison syndrome, multiple endocrine adenomas) (see clinical pharmacology in adults, clinical studies ). hypersensitivity to any component of these products. cross sensitivity in this class of compounds has been observed. therefore, famotidine injection should not be administered to patients with a history of hypersensitivity to other h2 -receptor antagonists.